Digital Expansion Hurdles

DocMorris AG (XSWX:DOCM) reported 2025 revenue growth of 11.1% and confirmed that it met its financial targets for the year, largely driven by a 110 % expansion in its digital services segment. The AI Health Companion has seen rapid uptake, with one‑third of app users engaging the assistant. The company’s strategic partnership with Google aims to further enhance its digital health platform. Despite this momentum, DocMorris faces challenges in reaching EBITDA break‑even in 2026 and free‑cash‑flow break‑even in 2027, citing modest growth in the EU segment, higher logistics and transport costs, and a negative net financial result driven by non‑cash effects. Liquidity remains robust, with CHF 160 million on hand. The company’s guidance hinges on RX growth, which is currently uncertain; to hit its mid‑term 15 % growth target, DocMorris expects RX growth of about 20 % initially, with stronger gains projected from 2028 to 2030. Online pharmacy market share in Germany has risen to roughly 1.7 % following the introduction of ERX, and the firm conservatively forecasts a 5‑6 % share within five years. DocMorris plans to manage liquidity by demonstrating a clear path to profitability and addressing refinancing needs once profitability is achieved.